- Clinical Pipeline
- Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
- Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
- Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
- ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
- Partnered Products and Programs
- Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
- Balversa® (erdafitinib) FGFr inhibitor (Oncology)
- Truqap® PKB/Akt Inhibitor (Oncology)
- KRAS Oncogene (Oncology)
- SHP2 (Oncology)
- P53 tumour suppressor protein (Oncology)
- Clinical Pipeline
- Pyramid™ Discovery Platform
- Oncology and CNS Discovery
- Sustaining Innovation
Below is our pipeline of investigational compounds that are currently in various stages of clinical development.
For more information on the pipeline of investigational compounds generated by Astex that are currently in clinical development at Taiho Oncology Inc., please follow the link here
For more information on the pipeline of products being developed globally at Otsuka, please follow the link here
Phase 1 | Phase 2 | Phase 3 |
---|
Tolinapant (ASTX660)
Antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP) (T-cell Lymphomas)
. | . |